Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma [0.03%]
食管鳞癌新辅助免疫治疗研究现状与挑战
Wanying Zhao,Sai-Qi Wang,Huifang Lv et al.
Wanying Zhao et al.
Neoadjuvant immunotherapy (NIT) is transforming the treatment landscape for esophageal squamous cell carcinoma (ESCC), substantially improving the pathological complete response (pCR) rates achieved with traditional chemoradiotherapy. Clini...
Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer [0.03%]
高级别浆液性卵巢癌中的线粒体代谢弱点
Anjali Prasad,Scott H Kaufmann,Arun Kanakkanthara
Anjali Prasad
High-grade serous ovarian cancer (HGSOC) is often programmed to rely heavily on mitochondrial metabolism, an adaptation that is linked to disease progression as well as resistance to standard treatments and immunotherapies. As such, mitocho...
Reprogramming ferroptosis in MDSCs: For state-dependent immunotherapy combinations [0.03%]
从MDSCs中铁死亡的重新编程到免疫治疗组合中的状态依赖性疗法
Yawen Li,Yuguang Zhao
Yawen Li
Ferroptosis of myeloid-derived suppressor cells (MDSCs) exerts state-specific and contextually regulated effects on antitumor immunity. Sublethal ferroptotic stress is characterized by lipid peroxidation and the release of prostaglandin E₂...
Decoding the metabolic-immune axis for novel therapeutics in bladder cancer [0.03%]
解读代谢免疫轴在膀胱癌新型治疗中的作用
Meiyan Zhou,Xiaoyan Xue,Huifang Li et al.
Meiyan Zhou et al.
Bladder cancer is a prevalent malignancy of the urinary system. Urothelial carcinoma is the predominant type, accounting for more than 90% of cases. The remaining histologic types include squamous cell carcinoma (approximately 2%-7%) and ad...
A bridge between embryonic development and disease: The converging regulatory roles of RKIP and YY1 [0.03%]
胚胎发育和疾病之间的桥梁：RKIP和YY1的交汇调节作用
Eda Acikgoz,Aysegul Taskıran,Gulperi Oktem
Eda Acikgoz
A principal challenge in modern biology and biomedical research is the comprehensive elucidation of the molecular and cellular mechanisms that underpin human disease, with the ultimate aim of identifying novel and effective therapeutic targ...
Cutting to the core: Proteases in the tumor-bone interface and metastatic progression [0.03%]
聚焦核心：肿瘤-骨骼界面的蛋白酶及转移进展
Ridhi Bhola,Reegan Sturgeon,Rakesh K Singh
Ridhi Bhola
Proteases are critical modulators of cancer progression, with matrix metalloproteinases (MMPs) and cathepsins playing central roles in the development and metastasis of breast and prostate cancers. These enzymes degrade and remodel the extr...
Cancer-associated fibroblasts in non-small cell lung cancer therapy: Challenges and opportunities [0.03%]
非小细胞肺癌治疗中的癌相关成纤维细胞：挑战与机遇
Siyou Deng,Yu Li,Lin Peng et al.
Siyou Deng et al.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related morbidity and mortality despite therapeutic advances. Current treatments offer limited benefit to many patients, a limitation closely linked to distinctive feature...
Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms [0.03%]
通过铁死亡机制解码肝细胞癌索拉非尼耐药性
Linlin Che,Liujing Zhu,Ling Zhou et al.
Linlin Che et al.
Sorafenib is a cornerstone in the treatment of advanced HCC. However, its clinical efficacy is frequently limited by the development of resistance, contributing to unfavorable patient outcomes. Overcoming this resistance is therefore a crit...
Gut-liver axis drives the triple mechanism of liver inflammation-carcinogenesis: Microbial-immune-metabolic network [0.03%]
肠肝轴驱动的肝脏炎症-癌变三重机制：微生物-免疫-代谢网络
Yuan-Dong Sun,Xiao-Gang Dong,Yi Chen et al.
Yuan-Dong Sun et al.
The gut-liver axis, through intricate microbial-immune-metabolic networks, plays a pivotal role in driving hepatic fibrosis. Chronic liver injury activates hepatic stellate cells, resulting in pathological extracellular matrix deposition. G...
Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies [0.03%]
抗血管生成药物联合免疫检查点抑制剂治疗消化系统肿瘤的研究进展及临床展望
Xiaoxuan Duan,Luqi Yan,Yingfei Wang et al.
Xiaoxuan Duan et al.
High heterogeneity and an immunosuppressive tumor microenvironment (TME) are the core therapeutic bottlenecks of digestive system tumors. Current monotherapies face prominent limitations: immune checkpoint inhibitors (ICIs) yield low overal...